Vimarsana
Biggest News Aggregation in the World

Page 17 - Data From News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Data From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Data From Today - Breaking & Trending Today

Ban on TikTok's use on US government devices likely to trigger more prohibitions - Vimarsana News

Ban on TikTok's use on US government devices likely to trigger more prohibitions

There could be more Congressional prohibitions against TikTok after a new ban on the use of Chinese social media app on US government devices with lawmakers kee

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in - Vimarsana News

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...

Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting - Vimarsana News

Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...